Prelude issued a press release on November 4, 2025, announcing its decision to pause the clinical development of its SMARCA2 degrader program. Prelude said that "[t]he decision to pause was based on a comprehensive review of clinical data generated to date and the Company's assessment of the capital and resource allocation required to advance the SMARCA2 program, versus the JAK2 and KAT6A programs, to key points of value inflection."
Following this news, Prelude's stock price fell over 55% on November 4, 2025.
To receive more information, please fill out the form.
